4.8 Article

Nucleosomes impede Cas9 access to DNA in vivo and in vitro

Journal

ELIFE
Volume 5, Issue -, Pages -

Publisher

ELIFE SCIENCES PUBLICATIONS LTD
DOI: 10.7554/eLife.12677

Keywords

-

Categories

Funding

  1. Howard Hughes Medical Institute
  2. National Institutes of Health [P50 GM102706, U01 CA168370, R01 DA036858]
  3. California Institute for Regenerative Medicine [RB4-06016]
  4. Leukemia and Lymphoma Society
  5. UCSF Medical Scientist Training Program

Ask authors/readers for more resources

The prokaryotic CRISPR (clustered regularly interspaced palindromic repeats) associated protein, Cas9, has been widely adopted as a tool for editing, imaging, and regulating eukaryotic genomes. However, our understanding of how to select single-guide RNAs (sgRNAs) that mediate efficient Cas9 activity is incomplete, as we lack insight into how chromatin impacts Cas9 targeting. To address this gap, we analyzed large-scale genetic screens performed in human cell lines using either nuclease-active or nuclease-dead Cas9 (dCas9). We observed that highly active sgRNAs for Cas9 and dCas9 were found almost exclusively in regions of low nucleosome occupancy. In vitro experiments demonstrated that nucleosomes in fact directly impede Cas9 binding and cleavage, while chromatin remodeling can restore Cas9 access. Our results reveal a critical role of eukaryotic chromatin in dictating the targeting specificity of this transplanted bacterial enzyme, and provide rules for selecting Cas9 target sites distinct from and complementary to those based on sequence properties.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available